Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.4
Journals
Medicina
Special Issues
Advancements and Outcomes in Transcatheter Aortic Valve Implantation (TAVI)
share announcement

Advancements and Outcomes in Transcatheter Aortic Valve Implantation (TAVI)

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 20 August 2026 | Viewed by 4396

Special Issue Editors

Prof. Dr. Dimitrios Iliopoulos

E-Mail Website
Guest Editor
1. Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
2. Department of Thoracic and Cardiovascular Surgery, UTHealth Houston, Houston, TX, USA
3. 4th Department of Cardiac and Aortic Surgery, Hygeia Hospital, Athens, Greece
Interests: adult cardiac surgery; aortic surgery; valve-sparing root replacement; high-risk cardiac surgery; aortic aneurysm
Special Issues, Collections and Topics in MDPI journals
Dr. Nikolaos Schizas

E-Mail Website
Guest Editor Assistant
Department of Cardiac Surgery, National and Kapodistrian University, Mikras Asias 75, 11527 Athens, Greece
Interests: cardiac surgery; aortic surgery;TAVI; endovascular aortic repair

Special Issue Information

Dear Colleagues,

We are currently witnessing the third decade of transcatheter aortic valve implantation (TAVI), a well-established approach to treating aortic valve diseases, especially aortic valve stenosis. The number of TAVI patients is growing rapidly, and its indications are expanding. Thus, it is essential that we enrich our knowledge in this field by collecting further data and outcomes.

This Special Issue will present the latest advancements in all aspects of TAVI, including clinical outcomes, new techniques, new devices, and comparisons with other approaches.

Current cutting-edge research focuses on indications, new devices, new methods, advancements in transcatheter interventions in aortic valve insufficiency or endocarditis, and re-interventions and probable complications.

We welcome the submission of original articles, reports on novel treatment strategies and advances in decision making, clinical outcome studies, comparative studies, narrative reviews, scoping reviews, and systematic reviews and meta-analyses.

Prof. Dr. Dimitrios Iliopoulos
Guest Editor

Dr. Nikolaos Schizas
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • TAVI
  • transcatheter aortic valve implantation
  • TAVR
  • aortic valve replacement
  • aortic valve stenosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 1336 KB  
Article
Prognostic Value of the CALLY Index in Predicting All-Cause Mortality After Transcatheter Aortic Valve Implantation: A Two-Year Follow-Up Study
by Zeynep Esra Güner, İsmail Balaban, Mustafa Ferhat Keten, Rıdvan Bolataslan, Ravza Betül Akbaş, Seda Tanyeri Üzel, Regayip Zehir and Elnur Alizade
Medicina 2026, 62(4), 755; https://doi.org/10.3390/medicina62040755 - 15 Apr 2026
Viewed by 592
Abstract
Background and Objectives: This study investigated the prognostic value of the C-reactive protein–albumin–lymphocyte (CALLY) index in predicting all-cause mortality among patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis. Materials and methods: This retrospective single-center study included 303 patients [...] Read more.
Background and Objectives: This study investigated the prognostic value of the C-reactive protein–albumin–lymphocyte (CALLY) index in predicting all-cause mortality among patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis. Materials and methods: This retrospective single-center study included 303 patients who underwent TAVI. The CALLY index and other established prognostic scores were calculated at baseline. Patients were followed for a median of 21 months. The primary endpoint was all-cause mortality. Results: A total of 60 patients (19.8%) died during follow-up. The CALLY index demonstrated the highest predictive performance for all-cause mortality, with an AUC of 0.698 (95% CI: 0.628–0.768, p < 0.001). In multivariate Cox regression, a low CALLY index remained an independent predictor of mortality (HR: 3.80, 95% CI: 2.03–7.11, p < 0.001), along with reduced LVEF, chronic kidney disease, and diabetes mellitus. Kaplan–Meier analysis further confirmed markedly worse survival in the high-risk group (log-rank p < 0.001). Conclusions: The CALLY index was independently associated with mortality after TAVI and may represent a complementary biomarker for risk stratification in this population. Full article
(This article belongs to the Special Issue Advancements and Outcomes in Transcatheter Aortic Valve Implantation (TAVI))
►▼ Show Figures

Figure 1

15 pages, 1426 KB  
Article
SGLT2 Inhibitor Therapy and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with Low Ejection Fraction
by Berhan Keskin, Aykun Hakgor, Yerkenur Khidolda, Atakan Dursun, Aysel Akhundova, Umeyir Savur, Fatih Erkam Olgun, Ozlem Onder, Yasar Gokhan Gul, Beytullah Cakal, Bulent Demir, Haci Murat Gunes, Ibrahim Oguz Karaca, Ekrem Guler and Bilal Boztosun
Medicina 2026, 62(3), 535; https://doi.org/10.3390/medicina62030535 - 13 Mar 2026
Viewed by 751
Abstract
Background and Objectives: Patients with impaired left ventricular ejection fraction (LVEF) undergoing transcatheter aortic valve implantation (TAVI) remain at high risk for adverse outcomes despite successful procedures. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in heart failure, but their long-term impact after TAVI [...] Read more.
Background and Objectives: Patients with impaired left ventricular ejection fraction (LVEF) undergoing transcatheter aortic valve implantation (TAVI) remain at high risk for adverse outcomes despite successful procedures. Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes in heart failure, but their long-term impact after TAVI is not well established. Materials and Methods: This single-center retrospective study included patients with LVEF < 50% who underwent transfemoral TAVI between January 2015 and September 2025. Patients were stratified according to SGLT2i use. The primary outcome was a composite of all-cause mortality and heart failure (HF) hospitalization requiring intravenous diuretics. Secondary outcomes included all-cause mortality, HF hospitalization, and changes in echocardiographic parameters at 6 months. Inverse probability of treatment weighting (IPTW) based on propensity scores was applied to adjust for baseline differences. Time-to-event analyses were performed using IPTW-weighted Cox models and adjusted survival curves. Results: The study included 226 patients (78 SGLT2i users, 148 non-users) with a median follow-up of 37 months. After IPTW adjustment, SGLT2i use was associated with a lower rate of the composite outcome (32.8% vs. 50.8%, p = 0.019) and a lower crude long-term mortality (32.8% vs. 47.4%, p = 0.056). Acute kidney injury after TAVI occurred less frequently among SGLT2i users (3.4% vs. 17.4%, p = 0.013). In IPTW-weighted Cox analyses, SGLT2i use was associated with a reduced risk of all-cause mortality (HR 0.57, 95% CI 0.32–0.98) and the composite outcome (HR 0.56, 95% CI 0.33–0.96). SGLT2i users demonstrated greater reductions in left ventricular end-diastolic diameter at 6 months. Conclusions: In patients with impaired LVEF undergoing TAVI, SGLT2 inhibitor therapy was associated with improved long-term survival, better composite outcome-free survival, and lower rates of post-TAVI acute kidney injury. Larger prospective studies are warranted to confirm these findings. Full article
(This article belongs to the Special Issue Advancements and Outcomes in Transcatheter Aortic Valve Implantation (TAVI))
►▼ Show Figures

Figure 1

14 pages, 505 KB  
Article
Transcatheter Versus Sutureless Aortic Valve Replacement: A Propensity-Matched Single-Center Cohort Study
by Nikoleta Stanitsa, Emmanouel Tempelis, Ilias Samiotis, Dimitris Oikonomou, Konstantinos Triantafyllou, George Lazopoulos, Periklis Tomos and Panagiotis Dedeilias
Medicina 2026, 62(3), 476; https://doi.org/10.3390/medicina62030476 - 3 Mar 2026
Viewed by 629
Abstract
Background and Objectives: Over the past decade, transcatheter aortic valve replacement (TAVI) has evolved from a treatment for inoperable patients to an established option across all risk categories. In parallel, the Perceval sutureless valve has demonstrated safety and efficacy especially for minimally [...] Read more.
Background and Objectives: Over the past decade, transcatheter aortic valve replacement (TAVI) has evolved from a treatment for inoperable patients to an established option across all risk categories. In parallel, the Perceval sutureless valve has demonstrated safety and efficacy especially for minimally invasive surgical aortic valve replacement (AVR). Despite the advances of both TAVI and Perceval, robust long-term data and clear patient selection criteria are still lacking. This retrospective single-center study reports the outcomes of patients undergoing isolated AVR with the Perceval sutureless valve or with TAVI. Materials and Methods: We retrospectively reviewed consecutive patients undergoing isolated AVR at our institution between April 2013 and December 2024. Of 1006 eligible patients (424 TAVI; 582 Perceval), propensity score matching was performed for age, sex, EuroSCORE II, body surface area, and comorbidities, yielding 197 matched pairs. Primary endpoints were all-cause and cardiovascular mortality. Secondary endpoints included acute kidney injury, permanent pacemaker implantation, stroke, pericardial effusion, ICU stay, and overall hospital stay. Clinical and echocardiographic follow-up was obtained by medical-record review and routine echocardiography, with an additional prospective clinical and echocardiographic evaluation at 6–12 months. Results: Postprocedural paravalvular leak was significantly more frequent after TAVI than after Perceval AVR (23.4% vs. 2.5%; p < 0.001). At 6–12 months, TAVI was associated with greater aortic regurgitation and higher rates of para- and intra-prosthetic leak (both p < 0.001) and higher mean transvalvular gradients, particularly in small and medium valve sizes. ICU and overall hospital stay were longer after Perceval implantation (both p < 0.001). New permanent pacemaker implantation was numerically higher after TAVI (11.2% vs. 5.6%; p = 0.063). Early mortality was similar; however, 1-year mortality was higher after TAVI (16.2% vs. 9.1%; p = 0.045), and Kaplan–Meier analysis demonstrated better overall survival with Perceval (p < 0.001), while cardiovascular survival did not differ significantly (p = 0.851). Conclusions: Our study underscores the importance of meticulous patient selection when choosing between TAVI and Perceval. Perceval implantation was associated with better long-term overall survival than TAVI in the propensity-matched cohort. Paravalvular leaks were more frequent after TAVI and associated with poorer survival. Both approaches achieve excellent outcomes; however, differences in long-term survival and valve performance highlight the need for a personalized treatment strategy guided by a multidisciplinary heart team. Full article
(This article belongs to the Special Issue Advancements and Outcomes in Transcatheter Aortic Valve Implantation (TAVI))
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 1722 KB  
Review
Transcatheter Aortic Valve Implantation in Low-Risk and Younger Patients with Porcelain Aorta: A State-of-the-Art Narrative Review
by Nikoleta Stanitsa, Michalis Tsibinos, Emmanouel Tempelis, Orestis Paliaroutas, Grigoris Trikas, Ilias Samiotis and Panagiotis Dedeilias
Medicina 2026, 62(3), 483; https://doi.org/10.3390/medicina62030483 - 4 Mar 2026
Viewed by 623
Abstract
Background and Objectives: Porcelain aorta is an anatomy-driven high-risk phenotype characterized by extensive calcification of the ascending aorta, which complicates surgical aortic valve replacement by increasing embolic and technical hazards during cannulation and cross-clamping. As transcatheter aortic valve implantation (TAVI) expands into younger [...] Read more.
Background and Objectives: Porcelain aorta is an anatomy-driven high-risk phenotype characterized by extensive calcification of the ascending aorta, which complicates surgical aortic valve replacement by increasing embolic and technical hazards during cannulation and cross-clamping. As transcatheter aortic valve implantation (TAVI) expands into younger and low-surgical-risk populations, porcelain aorta creates a distinct clinical dilemma: optimizing short-term procedural safety while ensuring durable long-term outcomes and preserving future treatment options. Materials and Methods: We performed a targeted literature search of MEDLINE/PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL), with the last search conducted on 31 January 2026. We synthesized contemporary clinical evidence on TAVI in patients with imaging-defined porcelain aorta, focusing on neurological outcomes, procedural strategies to reduce embolic risk, access considerations, valve performance, cerebral embolic protection, and implications for lifetime valve management (including coronary access and feasibility of future valve-in-valve interventions). Results: The evidence base specific to porcelain aorta in the contemporary TAVI era is limited and largely observational. Across published cohorts, TAVI avoids direct ascending aortic cannulation and cross-clamping and is generally associated with favorable early safety, with a recurring directional signal toward lower neurological risk compared with surgical strategies that require manipulation of a severely calcified ascending aorta. Interpretation is constrained by heterogeneity in porcelain-aorta definitions, patient selection, valve platforms and access routes, as well as, variability in neurological endpoint definitions and adjudication. Conclusions: In patients with porcelain aorta, TAVI is frequently favored because it minimizes ascending aortic manipulation and may mitigate neurological and procedural hazards. In younger and low-risk patients, Heart Team decision-making should incorporate lifetime management principles, including access planning, preservation of future coronary access, and procedural strategies to reduce embolic risk (with consideration of cerebral embolic protection when appropriate). Full article
(This article belongs to the Special Issue Advancements and Outcomes in Transcatheter Aortic Valve Implantation (TAVI))
►▼ Show Figures

Figure 1

13 pages, 1340 KB  
Review
A Narrative Review on Current Status of Conscious Sedation for Transcatheter Aortic Valve Implantation
by Georgia Nazou, Nikolaos Schizas, Konstantina N. Romana, Vasiliki Androutsopoulou, Eleni Magira, Andreas Sarantopoulos, Dimitrios Iliopoulos and Spyros D. Mentzelopoulos
Medicina 2025, 61(11), 1980; https://doi.org/10.3390/medicina61111980 - 5 Nov 2025
Viewed by 1200
Abstract
Anesthesiologic management of Transcatheter Aortic Valve Implantation (TAVI) is a key factor in procedural success and effectiveness. Although general anesthesia was the main anesthesiologic approach during the early years of the development of TAVI, over the last decade, there has been a shift [...] Read more.
Anesthesiologic management of Transcatheter Aortic Valve Implantation (TAVI) is a key factor in procedural success and effectiveness. Although general anesthesia was the main anesthesiologic approach during the early years of the development of TAVI, over the last decade, there has been a shift towards sedation. Hemodynamic stability is the main concern of intraoperative anesthesiologic management. Preprocedural, multidisciplinary assessment of the patient is essential prior to TAVI and should include a full anesthesiologic evaluation. TAVI offers a number of advantages to patients and medical teams, but important accompanying complications and anesthesiologic risks remain. In this narrative review, all aspects of sedation in TAVI are presented and analyzed, including methods, patient selection, contraindications, drug administration, intraprocedural parameters, outcomes, and future developments in this field. Full article
(This article belongs to the Special Issue Advancements and Outcomes in Transcatheter Aortic Valve Implantation (TAVI))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop